Purchase this article with an account.
L.F. Torres, P. Sánchez–Suarez, A.A. Rodriguez–Reyes, J.L. Diaz–Rubio, F. Saez–Espinola, D. Ríos, O.D. Torres, L. Monjes, L. Benítez–Bribiesca; Analysis of PCNA, p53, and bcl–2 Expression in the Sequence Primary Acquired Melanosis–Conjunctival Melanoma . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3409.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: The purpose of the present study was to examine the roles of p53, Bcl–2 and proliferating cell nuclear antigen (PCNA) in the progression of the sequence Primary Acquired Melanosis (PAM) –Conjunctival Melanoma (CM). Methods: Expression of p53, Bcl–2 and PCNA were detected by immunohistochemistry on paraffin–embedded sections of four cases with diagnosis of PAM with atypia and five cases of conjunctival melanoma from the Pathology Department of the Asociacion Para Evitar la Ceguera en Mexico, Hospital Dr. "Luis Sánchez Bulnes". Results: All cases showed a positive PCNA reaction. However, PCNA staining was increased in intensity in the conjunctival melanomas relative to PAM lesions. PCNA revealed a direct relationship between proliferation and malignant progression. Moreover, 60% of melanomas but none of the benign lesions presented a positive p53 immunostaining. In contrast to uveal melanomas, Bcl–2 expression was absent in both PAM and conjunctival melanomas samples. Conclusions: Expression of PCNA, a cell proliferation marker, increased from benign PAM to malignant lesions in all cases. Therefore, an hyperproliferative state may be a characteristic feature at all stages of malignant progression in this neoplasia. In contrast to uveal, but similar to cutaneous melanomas, Bcl–2 alteration may not participate in the molecular events underlying tumor development. Interestingly, p53 may have a pivotal role as a late mutation in the multistage process of melanoma carcinogenesis.
This PDF is available to Subscribers Only